Your session is about to expire
← Back to Search
Study Summary
This trial will compare itepekimab to placebo in smokers with COPD to see if it reduces exacerbations and improves pulmonary function.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am a current smoker and not planning to quit soon.I have had severe breathing issues that needed steroids or antibiotics.I have had severe lung flare-ups needing more than a day's hospital stay.I've been on a stable asthma treatment for at least 3 months.I have asthma or had it before I turned 18.I have not vaped any products in the last 6 months.I do not have active or latent TB, nor have I been in close contact with TB patients recently.I have been diagnosed with COPD for at least a year.I have had a chronic cough for at least 3 months in the past year, and it's not due to other known causes.I have or might have COVID-19, or I've been in close contact with someone who has it.I have smoked at least 10 pack-years and if I quit, it was more than 6 months ago.I have an active autoimmune disease or am on immunosuppressive therapy for one.I have irregular heartbeats, including occasional atrial fibrillation.I have had a chronic cough for at least 3 months in the past year, and it's not due to other common causes.I've had at least 2 moderate or 1 severe breathing flare-up in the last year, treated with steroids.I am between 40 and 85 years old.I need a BiPAP machine due to high carbon dioxide levels in my blood.I have moderate-to-severe chronic obstructive pulmonary disease.I am not able to have children or I agree to use birth control during and after the study.I am between 40 and 85 years old.I have previously used itepekimab.I have been diagnosed with COPD for at least a year.I have moderate-to-severe chronic obstructive pulmonary disease.I have been diagnosed with heart issues related to lung blood pressure.
- Group 1: Placebo in current smokers
- Group 2: Itepekimab Q2W in current smokers
- Group 3: Itepekimab Q2W in former smokers
- Group 4: Itepekimab Q4W in former smokers
- Group 5: Placebo in former smokers
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there other examples of scientific research using Itepekimab SAR440340?
"The first clinical trial for Itepekimab SAR440340 was in 2020. Since then, there have been a total of 18279 completed studies. Right now, there are 2 active trials taking place; many of these are located in Lampasas, Texas."
Can regular people join this trial at this time?
"The clinical trial is still recruiting patients, as shown by the information available on clinicaltrials.gov. The first posting was on February 12th, 2021 and the most recent update was on October 26th, 2022. This study seeks to enroll 1170 individuals at 100 different sites."
Does this research project restrict eligibility to people under 50 years old?
"The age requirements for this clinical trial are between 40 and 85 years old."
What is the US government's opinion of Itepekimab SAR440340?
"Itepekimab SAR440340 has some efficacy data supporting it and multiple rounds of safety data, so it was given a score of 3 for safety."
For which patient demographics is this study looking for participants?
"This trial is admitting 1170 patients with airflow obstruction and chronic aged 40 and 85. Most notable, patients must meet the following criteria: A physician diagnosis of COPD for at least 1 year (based on Global Initiative for Chronic Obstructive Lung Disease [GOLD] definition., Moderate exacerbations will be recorded by the Investigator and are defined as acute worsening of respiratory symptoms that requires either systemic corticosteroids (IM, IV, or oral) and/or antibiotics., Severe exacerbations will be recorded by the Investigator and are defined as AECOPD that require hospitalization or observation for >24 hours in emergency department"
Who else is applying?
How old are they?
What portion of applicants met pre-screening criteria?
What state do they live in?
What site did they apply to?
How many prior treatments have patients received?
Why did patients apply to this trial?
What questions have other patients asked about this trial?
How responsive is this trial?
Typically responds via
Average response time
- < 2 Days
Most responsive sites:
- Noble Clinical Research: < 24 hours
Share this study with friends
Copy Link
Messenger